Analysts Are Neutral on Top Healthcare PicksBy Jason Carr
Analysts fell to the sidelines weighing in on Lannett (NYSE: LCI) and Insys Therapeutics (NASDAQ: INSY) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks.
Lannett (NYSE: LCI)
According to TipRanks.com, Vanjani is a 4-star analyst with an average return of 4.7% and a 47.2% success rate. Vanjani covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, ANI Pharmaceuticals, and Endo International.
Lannett has an analyst consensus of Moderate Buy.
Insys Therapeutics (NASDAQ: INSY)
According to TipRanks.com, Ho is a 1-star analyst with an average return of -26.4% and a 0.0% success rate. Ho covers the Healthcare sector, focusing on stocks such as Endo International, Foamix Pharma, and Opko Health.
Currently, the analyst consensus on Insys Therapeutics is Moderate Buy and the average price target is $22, representing a 105.8% upside.
In a report released today, RBC Capital also reiterated a Hold rating on the stock.